By Frank Holmes

Even though the Federal Reserve announced last week that it would wait a little longer to raise rates, spooked investors fled to gold bullion, helping to drive prices above $1,200 an ounce. It was the greatest single-session surge by percentage in nearly a month and a half for the yellow metal, widely seen as a safe-haven investment. As I told MarketWatch, $1,200 is an important threshold for gold miners because it helps increase profitability and spur production.

The market move can be attributed not only to the Fear Trade—interest rate jitters and the Greek financial crisis—but also to the Love Trade. Heading into late June, the yellow metal has historically hit a trough and then rebounded on account of the approaching Indian festival and wedding seasons, a traditional time for gold gift-giving. I mentioned in a recent Frank Talk that in all but two of the past 27 years, gold and gold equities enjoyed a late summer rally, and that between 2001 and 2014, the metal posted an average 14.9-percent gain between midsummer and mid-autumn.

At the same time, it’s important for investors to keep in mind that gold has its own DNA of volatility. For the 12-month period over the last 10 years, gold’s volatility has been plus or minus 19 percent.

Other factors that could be influencing gold markets right now are China and, believe it or not, the State of Texas. The Asian giant is buying massive amounts of the metal to back the renminbi, which it purportedly wants to elevate to a world-class reserve currency. Similarly, Texas will be bringing home between $650 million and $1 billion worth of bullion from the Federal Reserve, as it’s in the early stages of creating the first state-run gold depository.

Global Pharmaceutical Spending Could Reach $1.3 Trillion by 2018

Besides gold, we’re also finding strength in health care, the best-performing S&P 500 Index sector for not only the week but also the one-, three-, five- and 10-year periods.

It’s easy to see why. According to health care information and technology company IMS Health, total pharmaceutical spending around the globe is expected to reach $1.3 trillion in just three years’ time. Although the U.S. remains the largest market in the world, China is set to experience the largest spending growth as its population continues to swell and incomes rise.

Indeed, in many parts of the world, the fastest-growing demographic is those aged 65 and older, a cohort that is much more likely to be prescribed medicines and require other health care treatments and services. Because of rising life expectancy, the number of centenarians—those over 100—is projected to grow 10-fold between 2010 and 2050, according to the National Institute on Aging.

As a result, the number of people over 65 will, for the first time ever, make up a larger percentage of the world’s population than those under five. This bifurcation should continue to widen as even more people live longer and reach advanced ages.

2015 Health Care M&As Expected to Top 2014’s Record $114 Billion 

Last year, health care companies benefited from a series of business deals, all of which totalled a record $114 billion. We’re only halfway through the year, and already we’ve seen close to $100 billion worth of mergers, acquisitions and other deals, one of the biggest being CVS’s takeover of Target’s pharmaceutical business for $2 billion.

Below, you can see how some of the growthier health care companies we hold in our Holmes Macro Trends Fund (MEGAX)—Canadian drug-maker Valeant,  insurance company Cigna and hospital-operator HCA Holdings—have outperformed the S&P 500 Health Care Index year-to-date. All three companies recently hit all-time highs.

Valeant, maker of a wide range of best-selling drugs, has managed to expand over the years through a host of strategic acquisitions, including eyecare company Bausch + Lomb and specialty pharma company Salix Pharmaceuticals. It’s reported that a Valeant insider has recently purchased $1.8 million in company stock, usually a good sign of future growth. Meanwhile, Cigna shares had a boost when the market learned that rival insurers Anthem and Aetna expressed interest in buying the Connecticut-based company.

Because of a growing (and aging) population and the emergence of a truly global middle class, we see health care as a strong performer for the long-term. Along with information technology and consumer discretionary, we are overweight health care right now, which has helped MEGAX beat its benchmark, the S&P Composite 1500 Index, year-to-date.   

This Asset Class Could Earn You More Income Than Treasuries, and It’s Tax-Advantaged

In a recent Barron’s article, investors are reassured that even though the municipal bond market has contracted for the last three months largely because of interest rate concerns, now might be a great time to get into shorter-term munis. In fact, according to Bloomberg, households are increasingly moving away from individual muni bonds and into actively-managed muni mutual funds.

Seekers of fixed income, Barron’s says, can earn more “from a triple-A rated muni maturing in 15 years than they can from a Treasury—roughly 2.8 percent versus 2.6 percent.”

The muni, moreover, is tax-free at the federal level and, in many cases, the state level.

Our Near-Term Tax Free Fund (NEARX) invests mostly in quality, short-term municipal bonds. Having provided investors with over 20 straight years of positive returns, NEARX holds five stars overall from Morningstar, among 185 Municipal National Short-Term funds as of 5/31/2015, based on risk-adjusted return.

Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a fund prospectus by visiting www.usfunds.com or by calling 1-800-US-FUNDS (1-800-873-8637). Read it carefully before investing. Distributed by U.S. Global Brokerage, Inc.

Past performance does not guarantee future results.

Total Annualized Returns as of 3/31/2015:

Expense ratio as stated in the most recent prospectus. The expense cap is a contractual limit through April 30, 2016, for the Near-Term Tax Free Fund, on total fund operating expenses (exclusive of acquired fund fees and expenses, extraordinary expenses, taxes, brokerage commissions and interest).Performance data quoted above is historical. Past performance is no guarantee of future results. Results reflect the reinvestment of dividends and other earnings. For a portion of periods, the fund had expense limitations, without which returns would have been lower. Current performance may be higher or lower than the performance data quoted. The principal value and investment return of an investment will fluctuate so that your shares, when redeemed, may be worth more or less than their original cost. Performance does not include the effect of any direct fees described in the fund’s prospectus which, if applicable, would lower your total returns. Performance quoted for periods of one year or less is cumulative and not annualized. Obtain performance data current to the most recent month-end at www.usfunds.com or 1-800-US-FUNDS.

Morningstar Ratings are based on risk-adjusted return. The Morningstar Rating for a fund is derived from a weighted-average of the performance figures associated with its three-, five- and ten-year Morningstar Rating metrics. Past performance does not guarantee future results. For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund’s monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.)

Bond funds are subject to interest-rate risk; their value declines as interest rates rise. Though the Near-Term Tax Free Fund seeks minimal fluctuations in share price, it is subject to the risk that the credit quality of a portfolio holding could decline, as well as risk related to changes in the economic conditions of a state, region or issuer. These risks could cause the fund’s share price to decline. Tax-exempt income is federal income tax free. A portion of this income may be subject to state and local taxes and at times the alternative minimum tax. The Near-Term Tax Free Fund may invest up to 20% of its assets in securities that pay taxable interest. Income or fund distributions attributable to capital gains are usually subject to both state and federal income taxes.

Stock markets can be volatile and share prices can fluctuate in response to sector-related and other risks as described in the fund prospectus.

The S&P 500 Stock Index is a widely recognized capitalization-weighted index of 500 common stock prices in U.S. companies. The S&P 1500 Composite is a broad-based capitalization-weighted index of 1500 U.S. companies and is comprised of the S&P 400, S&P 500, and the S&P 600.  The index was developed with a base value of 100 as of December 30, 1994. The S&P 500 Healthcare Index is a capitalization-weighted index.

Fund portfolios are actively managed, and holdings may change daily. Holdings are reported as of the most recent quarter-end. Holdings in the Holmes Macro Trends Fund and Near-Term Tax Free Fund as a percentage of net assets as of 3/31/2015: IMS Health Holdings Inc. 0.00%, CVS Health Corp. 0.00%, Target Corp. 0.00%, Cigna Corp. 0.00%, Valeant Pharmaceuticals International Inc. 0.00%, HCA Holdings Inc. 0.00%, Bausch & Lomb Inc. 0.00%, Salix Pharmaceuticals Inc. 0.00%, Athem Inc. 0.00%, Aetna Inc. 1.14%.

All opinions expressed and data provided are subject to change without notice. Some of these opinions may not be appropriate to every investor. By clicking the link(s) above, you will be directed to a third-party website(s). U.S. Global Investors does not endorse all information supplied by this/these website(s) and is not responsible for its/their content.

| Digg This Article
 -- Published: Monday, 22 June 2015 | E-Mail  | Print  | Source: GoldSeek.com

comments powered by Disqus
Previous Articles